Hoth Therapeutics Shares Soar on Positive Data from Alzheimer's Study

Dow Jones03-19

By Dean Seal

Shares of Hoth Therapeutics soared after the company announced positive data in a completed pre-clinical study of its Alzheimer's Disease therapeutic HT-ALZ.

The stock was up 32% at $1.52 in early trading. Shares are now in positive territory year-to-date.

The New York-based biopharmaceutical company said Tuesday morning that pre-clinical research shows HT-ALZ combating neuroinflammation and diminishing anxiety-like behavior associated with Alzheimer's Disease.

The research presents what Hoth is calling compelling evidence of the treatment's capacity for improving memory tasks related to the hippocampus and sensorimotor gating.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

March 19, 2024 10:15 ET (14:15 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2420127866?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-19 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2420127866","market":"hk","top_or_hot":-1,"title":"Hoth Therapeutics Shares Soar on Positive Data from Alzheimer's Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> soared after the company announced positive data in a completed pre-clinical study of its Alzheimer's Disease therapeutic HT-ALZ. \n</p>\n<p>\n  The stock was up 32% at $1.52 in early trading. Shares are now in positive territory year-to-date. \n</p>\n<p>\n  The New York-based biopharmaceutical company said Tuesday morning that pre-clinical research shows HT-ALZ combating neuroinflammation and diminishing anxiety-like behavior associated with Alzheimer's Disease. \n</p>\n<p>\n  The research presents what Hoth is calling compelling evidence of the treatment's capacity for improving memory tasks related to the hippocampus and sensorimotor gating. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 19, 2024 10:15 ET (14:15 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Shares Soar on Positive Data from Alzheimer's Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Shares Soar on Positive Data from Alzheimer's Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-19 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Dean Seal \n\n\n \n\n\n  Shares of Hoth Therapeutics soared after the company announced positive data in a completed pre-clinical study of its Alzheimer's Disease therapeutic HT-ALZ. \n\n\n  The stock was ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01611","symbol_name":"新火科技控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2420127866","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2420127866","pubTimestamp":1710857700,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Hoth Therapeutics soared after the company announced positive data in a completed pre-clinical study of its Alzheimer's Disease therapeutic HT-ALZ.The stock was up 32% at $1.52 in early trading. Shares are now in positive territory year-to-date.The New York-based biopharmaceutical company said Tuesday morning that pre-clinical research shows HT-ALZ combating neuroinflammation and diminishing anxiety-like behavior associated with Alzheimer's Disease.The research presents what Hoth is calling compelling evidence of the treatment's capacity for improving memory tasks related to the hippocampus and sensorimotor gating.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01611":"新火科技控股","BK4007":"制药","BK1167":"电子制造服务","HOTH":"Hoth Therapeutics"},"translate_title":"阿尔茨海默氏症研究的积极数据推动霍斯治疗公司股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":1,"01611":0.77},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Hoth Therapeutics soared after the company announced positive data in a completed pre-clinical study of its Alzheimer's Disease therapeutic HT-ALZ. \n\n\n  The stock was up 32% at $1.52 in early trading. Shares are now in positive territory year-to-date. \n\n\n  The New York-based biopharmaceutical company said Tuesday morning that pre-clinical research shows HT-ALZ combating neuroinflammation and diminishing anxiety-like behavior associated with Alzheimer's Disease. \n\n\n  The research presents what Hoth is calling compelling evidence of the treatment's capacity for improving memory tasks related to the hippocampus and sensorimotor gating. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2024 10:15 ET (14:15 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2420127866"}